News Releases

Month Year

Email Alerts

Jan 4, 2018

Veltassa® approved for marketing in Switzerland for the treatment of Hyperkalaemia

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
Nov 23, 2017

Third Global Iron Deficiency Day to Raise Awareness of the Symptoms of Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Sep 27, 2017

Vifor Pharma Expands Exclusive License Agreement for the Commercialisation of Mircera® in the Us

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Aug 8, 2017

Vifor Pharma Reports Strong H1 2017 Results and Raises Guidance

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 21, 2017

European Commission Approves Marketing Authorisation for Veltassa®

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 18, 2017

New Expert Review in the American Journal of Hematology Seeks to Change the Way We Test, Treat and Talk About Iron Deficiency in Chronic Inflammatory Conditions

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jul 12, 2017

Vifor Pharma Announces Three Outcomes Trials in Heart Failure and Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Jun 9, 2017

Kissei to Market Avacopan in Japan for Vifor Fresenius Medical Care Renal Pharma

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 19, 2017

Chmp Recommends Veltassa® for the Treatment of Hyperkalaemia in the Eu

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
May 16, 2017

Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.s. Upon Fda Approval

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

Show per page

Filter by Company: